Medtronic’s MiniMed 780G automated insulin delivery system received FDA clearance to use ultra‑rapid‑acting insulins Fiasp and Lyumjev and to pair with Abbott’s Instinct sensor for patients with insulin‑requiring type 2 diabetes. The clearance also authorizes Medicare and Medicare Advantage beneficiaries to obtain the system with the Instinct sensor, adding a new sensor option to the existing Simplera Sync and Guardian 4 choices and enabling coverage under standard Medicare billing and fulfillment processes.
The MiniMed 780G automatically adjusts insulin delivery every five minutes, and the Instinct sensor offers a 15‑day wear time while remaining the world’s smallest, thinnest, and most discreet integrated continuous glucose monitor. The FDA approval for type 2 diabetes marks the first automated insulin delivery system with meal‑detection technology available to that population, aligning with the American Diabetes Association’s updated Standards of Care that endorse AID systems for intensive insulin‑treated type 2 patients.
The approvals broaden the system’s addressable market, potentially increasing adoption among older adults and Medicare beneficiaries who previously had limited access to advanced diabetes technology. By expanding sensor choice and enabling Medicare coverage, Medtronic positions the MiniMed 780G to capture a larger share of the growing automated insulin delivery segment, which is expected to drive incremental revenue as the company’s diabetes portfolio matures.
Strategically, the clearance supports Medtronic’s plan to spin off its diabetes business into a standalone company within the next 18 months. The expanded indications and Medicare access strengthen the business’s value proposition, reinforcing the company’s focus on high‑margin, high‑penetration growth drivers and aligning with the broader industry shift toward integrated, patient‑centric solutions.
Que Dallara, EVP and President of Medtronic Diabetes, said the milestones “reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition.” The statement underscores the company’s emphasis on patient access as a key lever for future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.